Explore our newest products
We are a world leader in pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications.
Find out more information on our newest products:

Sustainably sourced squalene (early 2024)
Introducing our sugar-derived squalene, produced using cutting-edge technology that centres on synthetic biology, our pharmaceutical-grade squalene has superior purity and carries the same squalene benefits as shark-derived squalene.

Sustainable saponins (2024)
As we look to become more nature positive, we’re proud to be able to offer our next-generation QS 21 and support global sustainability efforts. Our next-generation QS 21 is based on plant tissue culture, which makes the process more efficient and sustainably sourced.

Introducing Virodex™
We’re introducing our new range of detergents specifically designed to support the key steps in your biomanufacturing processes. The Virodex™ range for viral inactivation and cell lysis is REACH-compliant, compendial, sustainable, and has been optimised for use in biomanufacturing of recombinant proteins, blood fractionation products, viral vectors, and more.
How we empower biologics delivery


Access to specialist formulation support
Enabling over 250 on-going clinical projects targeting a range of therapeutic areas across biologics and small molecules